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Breast cancer is a prevalent disease worldwide, and the majority of deaths occur due to metastatic disease. Clinical studies have
identiﬁed a speciﬁc pattern for the metastatic spread of breast cancer, termed organ tropism; where preferential secondary sites
include lymph node, bone, brain, lung, and liver. A rare subpopulation of tumor cells, the cancer stem cells (CSCs), has been
hypothesized to be responsible for metastatic disease and therapy resistance. Current treatments are highly ineﬀective against
metastatic breast cancer, likely due to the innate therapy resistance of CSCs and the complex interactions that occur between
cancer cells and their metastatic microenvironments. A better understanding of these interactions is essential for the development
of novel therapeutic targets for metastatic disease. This paper summarizes the characteristics of breast CSCs and their potential
metastatic microenvironments. Furthermore, it raises the question of the existence of a CSC niche and highlights areas for future
investigation.
1.Introduction
Due to the expanding and aging global population, it is no
surprise that cancer incidence and mortality are increasing
despite ongoing research in the areas of cancer treatment
and prevention. In North American women, breast cancer
represents the most commonly diagnosed and the second
highest cause of cancer-related deaths [1, 2]. Although the
collection of exact global cancer statistics is diﬃcult due to
diﬀerences in healthcare infrastructure and data collection
methods, the GLOBOCAN study ranks breast cancer as the
most frequently diagnosed and the most prevalent cause
of cancer-related death among women globally [3]. In the
past, breast cancer has been a higher burden in developed
countries, likely due to more risk factors associated with
lifestyle such as postponement of pregnancy until after 30,
less breast-feeding, smaller families, and a less active work-
place[4].Itispredictedthatasdevelopingcountriesimprove
their economic conditions and adopt a more “westernized”
lifestyle, incidence rates will increase [5]. The challenge then
presents itself: what is the best way to target this lethal
disease in developed countries while also counteracting the
predicted increase in mortality in developing countries? The
answer lies in the understanding of metastatic disease, the
most lethal aspect of breast cancer.
2.Metastasis
Even though advances have been made in prevention,
detection, and treatment, the mortality rate associated with
breast cancer has remained high [3]. Primary breast tumors
originate within the lobule or duct of the breast, and2 International Journal of Breast Cancer
therapies are highly eﬃcient if the neoplasm is detected
while localized within the original structure (in situ)o r
even still localized within the breast itself [6]. Therapeutic
eﬃcacy is greatly reduced once the cancer acquires invasive
and metastatic properties. Therefore, metastatic disease
represents the aspect of breast cancer responsible for the
majority of breast-cancer-related mortalities.
Following successful angiogenesis at the primary tumor
site, the stepwise process of metastasis has been clearly
deﬁned. During the initial stage, cells escape from the
primary tumor into the blood and/or lymphatic system via
a process called intravasation. Once in the circulation, these
cellsmustsurviveuntiltheyreachasecondarysitewherethey
arrestandenterthetissue(extravasation).Tumorcellsableto
initiate and maintain colony growth in these secondary sites
form micrometastases which, following angiogenesis, grow
into clinically detectable macrometastases [7–9].
3. MetastaticTheories
Clinical observations highlight that diﬀerent cancers exhibit
characteristic sites for secondary metastases that are depen-
dent on the origin of the primary tumor, a phenomenon
termed organ tropism [10, 11]. For example, breast cancer
preferentially spreads to the lymph nodes, lung, liver, bone,
and brain, while other primary cancers have diﬀerent
preferential sites of metastasis (i.e., prostate cancer and
colorectal cancer spread to bone and liver, respectively) [11].
While there are many theories concerning the mechanisms
of metastasis (eloquently summarized by Hunter et al.
[12]), only a few suﬃciently account for the organ tropism
phenomenon. Two of the main theories that have been
proposed to explain this organ tropism of cancer metastasis
include the “seed and soil” theory, ﬁrst documented by
Stephen Paget in 1889, and Ewing’s mechanical arrest theory
[13, 14]. Paget postulated that organ-speciﬁc patterns could
be accounted for by the needs of the cancer cell (the seed)
for a speciﬁc environment (the soil) in order to initiate
and maintain growth [13]. Ewing’s theory, proposed thirty
years later, postulates that organ tropism can be accounted
for by circulatory patterns within the body and that cells
are mechanically arrested in the ﬁrst capillary bed they
encounter [14]. It is likely that these two theories are not
mutually exclusive, but rather that they work in concert to
produce successful metastases: cells arrest due to mechanical
obstructionand/orspeciﬁcchemicalsignalsandthenrequire
a suitable microenvironment for initiation and maintenance
of secondary tumor growth.
An autopsy study by Dr. Leonard Weiss [10] addressed
the diﬀerences between the “seed and soil” and mechanical
arrest theories by not only investigating the incidence of
metastatic lesions at secondary sites, but by also taking into
account the innate blood ﬂow to each of the sites. This study
usedthesetwoparameterstogeneratea“metastaticeﬃciency
index” (MEI) that was used to rank pairs of primary and
secondary sites as either accounted for by blood ﬂow alone,
or as “friendly” (more incidence than suggested by blood
ﬂow patterns alone) versus “hostile” (less incidence than
dictated by blood ﬂow) interactions. Interestingly, 66% of
the pairs could be attributed to blood ﬂow due to the sheer
number of cancer cells delivered to the sites in arterial blood
(i.e., mechanical arrest), while 20% of pairs were ranked
as “friendly” and 14% of pairs were deemed to be due to
“hostile” interactions. Of note, prostate and breast cancer
were seen to exhibit a “friendly” interaction with bone; while
ovarian, prostate, stomach, and urinary bladder cancers
were seen to have a “hostile” interaction with the brain
[10]( Table 1). This study suggests that some site-speciﬁc
metastases can be attributed to blood ﬂow patterns, but that
there is also a distinct seed and soil eﬀect for others. The
question of whether the properties of the secondary organ
or the properties of the cancer cell are more important in
mediating the organ tropism of breast cancer remains to be
answered.
4. MetastaticInefﬁciency
Although often lethal when successful, the multistep nature
of the metastatic process lends itself to a high degree of
ineﬃciency. In an experimental mouse model, Luzzi et al.
used in vivo videomicroscopy to demonstrate that only
0.02% of melanoma cells injected intraportally to target the
livercouldsuccessfullycompletetheentiremetastaticprocess
[15]. Interestingly, the authors noted that not all metastatic
stages are equally ineﬃcient, but rather that the main
ineﬃciencies occur during the initiation and maintenance of
metastatic lesions in the secondary organ. Many tumor cells
are capable of extravasating into the secondary site, but may
become dormant due to lack of external growth signals [16],
and/or may fail to colonize the site due to a lack of ability to
recruit suﬃcient blood supply to support the formation of a
clinically relevant lesion.
This ineﬃciency appears to be mirrored in humans
as, in a limited study of palliative ovarian cancer patients,
ascites ﬂuid full of tumor cells that was shunted directly
into the venous circulation via peritoneovenous shunts did
not always cause secondary lesions. Some but not all of
these cases resulted in pulmonary metastases, although these
lesions were clinically irrelevant as patient mortality resulted
ﬁrst from primary tumor progression. Other cases did not
develop detectable metastatic lesions within the timeframe
of the study (up to 27 months) before they too succumbed to
their original tumor [17]. Both murine and human studies
suggest that only a rare subpopulation of primary tumor
cells can successfully complete the metastatic process, and
likely the outcome also depends on the secondary organ
microenvironment. Our group and others hypothesize this
rare subpopulation of tumor cells to be cancer stem cells
(CSCs) [18–21].
5. Cancer Stem Cells
The composition of primary breast tumors has been shown
to be heterogeneous with respect to both molecular subtype
(luminal A, luminal B, basal-like, HER2-overexpressing,
normal breast-like, and claudin-low) [22, 23]a n dc e l l u l a r
function, even within the same tumor [24, 25]. This
heterogeneity can be accounted for by the CSC hypothesis,International Journal of Breast Cancer 3
Table 1: Interactions between primary cancer site and target organ based on metastatic eﬃciency indexes.
Primary cancer
site
Target organ
Kidney Brain Bone Skeletal
muscle Skin Heart Thyroid Adrenal
B o n e — — ——— / —
  ⏐
Breast — —
  ⏐ —— —
  ⏐   ⏐
C e r v i x ——— —
⏐   /
  ⏐   ⏐
Colorectal — — —
⏐   ———
  ⏐
E s o p h a g u s ——— —
⏐   /
  ⏐   ⏐
Kidney — — —
⏐   ——
  ⏐   ⏐
L u n g ——— / / ——
  ⏐
Lung(SCC) — — — / / / —
  ⏐
Osteosarcoma
⏐   ⏐   —
⏐   /
⏐   —
⏐  
Ovary
⏐   ⏐   —/— —
  ⏐   ⏐
Ovary∗ —
⏐   ——— / —
  ⏐
P a n c r e a s ——— — ———
  ⏐
Prostate — —
  ⏐ —
⏐   ⏐   —
  ⏐
Prostate∗ —
⏐     ⏐ /
⏐   ——
  ⏐
Stomach —
⏐   —
⏐   —/—
  ⏐
T e s t i s ———
⏐   —/—
  ⏐
T h y r o i d — — ——— / —
  ⏐
Urinary Bladder —
⏐   ——— /
  ⏐   ⏐
U t e r u s ——— —
⏐   /
  ⏐   ⏐
Adapted from Weiss (1992) [10].   ⏐ Friendly (Increased incidence) (MEI > 0.100). ⏐   Hostile (Decreased incidence) (MEI < 0.009).
— Neutral (0.010 < MEI < 0.099).
/N o tr e p o r t e d .
SCC: small cell carcinoma.
∗Duplicate sites due to diﬀerent autopsy studies used.
also known as the hierarchy theory, which posits that there is
a small, phenotypically identiﬁable subpopulation of cancer
cells with stem cell-like characteristics [26]. These CSCs sit
at the top of this functional hierarchy and are postulated
to be capable of tumor propagation and maintenance due
to their ability to self-renew and to diﬀerentiate into the
cells comprising the bulk of the tumor. Conversely, the
terminally diﬀerentiated non-CSCs are not capable of pro-
ducing large amounts of progeny or of tumor propagation
[25, 27, 28].
The ﬁrst identiﬁcation of CSCs in solid tumors came
from the seminal work of Dr. Michael Clarke’s group [29]
following the lead of Dr. John Dick and colleagues in
the leukemia ﬁeld [30]. Working with cells isolated from
the pleural eﬀusions and primary tumors of breast cancer
patients, Al-Hajj et al. [29] isolated distinct subpopulations
of tumor cells using ﬂuorescence-activated cell sorting. The
epithelial-speciﬁc antigen positive (ESA+) CD44+ CD24
−/low
lineage negative (Lin−) subpopulation was capable of form-
ing tumors when as few as 100 cells were injected into
the mammary fat pad of nonobese diabetic/severe com-
bined immune deﬁciency (NOD/SCID) mice, whereas tens
of thousands of cells from other subpopulations were non-
tumorigenic. Ginestier et al. [31] further puriﬁed this breast
CSCsubpopulationbyaddinginthecriteriaofhighaldehyde
dehydrogenase activity (ALDHhi). ALDHhi CD44+ CD24−
breast tumor cells were capable of tumor initiation when
as few as 20 cells were injected into NOD/SCID mice.
These tumors exhibited the same phenotypic heterogeneity
as the initial tumors, exhibiting both tumorigenic and
nontumorigenic subpopulations. Furthermore, this tumor
formationandheterogenicrecapitulationcouldbereplicated
upon serial passaging in na¨ ıve NOD/SCID mice of the
ALDHhi CD44+ CD24− cells isolated from tumors derived
from the initial CSC injection, demonstrating the CSCs’
diﬀerentiation and self-renewal potential [31].
Breast CSCs demonstrate an increased metastatic
propensity in vitro [18, 32, 33], in vivo [18, 21, 34], and in
clinical observation [20, 35]. Although their metastatic role
is not fully understood, many theories have attempted to
explain the contribution of CSCs to breast cancer metastasis.
The most common site of breast cancer metastasis is to the
bone, but metastatic lesions are also found in the lungs,
brain, and liver [11]. The high level of CD44 expression by
CSCs has been highlighted as one possible contributor, as
both hyaluronan and osteopontin (OPN), common ligands
for CD44, are expressed in the bone and other common
sites of metastasis [36], suggesting a possible adhesive4 International Journal of Breast Cancer
interaction for circulating tumor cell arrest. In vitro, the
CD44-hyaluronaninteractionhasbeenshowntomediatethe
attachment of metastatic breast cancer cells to human bone
marrow endothelial cells [37]. Moreover, this interaction
could be abrogated through the depletion of CD44 expres-
sion using RNA interference and induced by the transfection
of a CD44low breast cancer cell line with CD44 expression
vectors [37]. Additionally, breast cancer cell lines exhibit
diﬀerent levels of Chemokine (C-X-C motif) Receptor 4
(CXCR4), which appears to positively correlate with both
CSC proportions and the propensity of breast cancer cell
lines to metastasize [18, 38]. Similar observations were made
in pancreatic cancer, where within the identiﬁed CD133+
CSC population, there existed two subpopulations based on
CXCR4 expression, and only the CXCR4+ population was
capable of metastasizing [39]. Although the mechanisms
have not yet been elucidated, there is evidence to suggest that
CSCs are not only tumor-initiating cells, but also metastasis-
initiating cells (M-ICs). The role of CSCs in driving organ
tropism of breast cancer remains to be determined.
Recent work has also highlighted that CSCs isolated from
tumors originating in the breast and other tissues exhibit
resistance to chemotherapy and radiation [40–43]. A study
of human leukemia revealed that the chemoresistance of
leukemic CSCs arises from the quiescent nature of these
cells, as they are stationary in the G0 phase, which limits
the eﬀectiveness of chemotherapeutics that target actively
replicating cells [44]. In humans, an increase in the pro-
portion of CD44+ CD24− breast cancer cells has been
observed after neoadjuvant chemotherapy, indicating likely
CSC therapy resistance in vivo [19]. Possible mechanisms for
this include the expression of cell surface drug eﬄux pumps,
such as breast cancer resistance protein-1 (BCRP1; ABCG2),
which are capable of expelling chemotherapeutic drugs [45].
Interestingly, BCRP1 is also highly expressed in normal
hematopoietic stem cells [46]. Additionally, the presence and
activity of ALDH, an enzyme that is capable of metabolizing
and inactivating cytotoxics such as cyclophosphamide [47],
is likely playing a key role in the observed chemoresistance.
Other factors potentially prolonging the lifespan of CSCs
include the increased expression of antiapoptotic molecules
such as Bcl-2 and survivin [48, 49]. It remains unclear
whether this observed metastatic ability and resistance to
therapy is a property attributable only to the CSCs (i.e.,
innate therapy resistance), or whether these specialized cells
also receive signals from their microenvironment in the
secondary organ that enhance their survival and resilience in
the face of cytotoxic treatment. New therapeutic targets may
therefore emerge as we gain a greater understanding of the
organ-speciﬁc interactions between tumor cells (the “seeds”)
and secondary organ sites (the “soil”).
6. CSCsandthe MetastaticMicroenvironment
Therearetwoprevailingschoolsofthoughtastotheoriginof
theCSC:either(1)aCSCmayoriginatefromanormaltissue
stem cell (SC) that has acquired tumorigenic mutations; or
(2) a CSC may originate from a more diﬀerentiated progeni-
tor/mature cell that has dediﬀerentiated and adapted a stem-
like phenotype. Both theories remain under investigation.
Recent work by Gupta et al. supports the latter theory by
demonstrating that subpopulations within the SUM149 and
SUM159 breast cancer cell lines are capable of interconver-
sionbetweenstem-like,basal,andluminalpopulations.They
demonstrate that a phenotypic equilibrium is consistently
reached over time both in vitro and in vivo, although the
in vivo growth requires coinjection of basal or luminal cells
with irradiated carrier cells to allow for these two subtypes to
persist long enough to give rise to stem-like cells [50]. The
rate at which this interconversion occurs depends only on
the current subpopulation of a cell and is not inﬂuenced by
the history of the cell. In support of this, Scaﬃdi and Misteli
successfully generated CSC-like and non-CSC-like cells after
oncogenic reprogramming of diﬀerentiated ﬁbroblasts. They
observed a stochastic emergence of a small population of
CSC-like cells expressing stage-speciﬁc embryonic antigen
1 (SSEA-1), a marker that did not arise in any of their
control lines, suggesting that the CSC phenotype may occur
spontaneouslyafterthemainoncogeniceventshaveoccurred
[51]. Further work that supports this “dediﬀerentiation” of
non-CSCs into CSCs demonstrates the possibility that IL-6
m a yb eak e ym e d i a t o ro ft h ep r o c e s s[ 52] and highlights the
need forfurtherinvestigation into the origin of CSCs and the
eﬀects of their microenvironment on regulating this cellular
plasticity.
Regardless of their origin, the functional similarities
between CSCs and normal SCs are striking. Normally, the
SCnicheprovidessignalsthateithermaintainSCquiescence,
promote symmetrical division leading to self-renewal, or
promoteasymmetricaldivisionleadingtodiﬀerentiationand
progression down the lineage [53]. Interactions between
SCs and their niche are highly dynamic and essential for
proper function [54]. As SCs depend on the surrounding
microenvironment for important signals, it is not unrea-
sonable to hypothesize that CSCs may also rely on their
microenvironment to maintain their tumor-initiating and
metastasis-initiating capacity and that a “metastatic niche”
may exist in those organs in which these cells are more
likely to create metastatic lesions. This niche may play an
important role in the organ tropism observed in breast and
other cancers. Additionally, signals from the metastatic niche
maycausethe interconversion of non-CSCs thathave arrived
from the primary tumor into more metastatic CSCs.
7. Seed andSoil Interactionsin
theMetastaticNiche
In the bone marrow, there are functionally diﬀerent
hematopoietic stem cell niches depending on physical loca-
tion [53, 55]. Synonymously, the metastatic niches around
the body may vary, thus dictating what types of cancer cells
will be successful in various secondary organs and contribut-
ing to the observed organ tropism of diﬀerent cancer types.
The next part of this paper summarizes what is currently
known aboutthe metastatic microenvironments provided byInternational Journal of Breast Cancer 5
common sites of breast cancer metastasis, including bone,
brain, lung, liver, and lymph node (Figure 1).
7.1. Bone. Bone is one of the main sites of metastasis for
breast cancer, and many groups postulate that this is due
to the rich nature of the niche, as it is already optimized
for support of normal hematopoiesis [60, 61]. Bone cells
express high amounts of stromal-derived factor 1 (SDF-
1), which may allow for breast cancer cell migration in
aC X C R 4 +-dependent manner [62]. Additionally, the bone
microenvironment is rich in ligands such as OPN, which
may further support CSC recruitment to the bone through
interactions between tumor cell-surface receptors such as
CD44 [36, 55]. When a breast cancer cell line variant was
selected in vivo for increased metastatic capacity for bone,
genotypic analysis revealed the upregulation of many genes
relative to those expressed by an adrenal medulla seeking
variant of the same cell line, including CXCR4, ﬁbroblast
growth factor-5 (FGF-5), connective tissue-derived growth
factor, interleukin-11 (IL-11), and matrix metalloproteinase
1 (MMP1). This suggests that these cells have innate capabil-
ities to interact with the bone microenvironment, including
promotion of both angiogenesis and osteolysis through the
diﬀerentiation of osteoclasts or cleavage of collagen [57].
Once in the bone, tumor cells exert a profound eﬀect on
the bone microenvironment, known as the “vicious cycle”
[61]. Normally, the bone is a highly dynamic structure, con-
stantly undergoing remodeling in a carefully regulated bal-
ance of osteoblast-mediated bone formation and osteoclast-
mediated bone resorption. Breast cancer commonly causes
osteolytic bone metastases, indicating the balance has shifted
infavorofbonedegradation.Inaclinicalstudyofbreastcan-
cer metastases to the bone, 92% of bone metastases scored
high by immunohistochemistry for parathyroid-hormone-
related protein (PTHrP) compared to 17% in nonbone
sites [63], an observation that was further supported by
similar in situ hybridization results [64]. It is thought that
PTHrP plays an important role in mediating osteolytic bone
metastases[65].ThesecretionofPTHrPcausesosteoblaststo
increase their expression of the membrane protein receptor
activator of nuclear factor κB (RANK) ligand (RANKL),
which promotes osteoclast precursor diﬀerentiation and
activationthroughRANKactivation[66].Degradationofthe
bone matrix causes the release of growth factors, including
transforming growth factor-β (TGF-β), insulin-like growth
factors I and II (IGF-I and II), platelet-derived growth
factor (PDGF), FGF-1 and -2, and bone morphogenic
proteins (BMP), all of which have eﬀects on both osteoblasts
and tumor cells [67], causing an increase in tumor cell
secretion of PTHrP and the propagation of the vicious
cycle. Additionally, these growth factors enter the systemic
circulation where they have potential to stimulate cells
at distant sites, potentially creating additional metastatic
niches and permitting tumor spread. Interestingly, in a
large prospective study involving 526 patients aﬄicted with
operable breast cancer, Henderson et al. found that positive
PTHrP staining in the primary tumor correlated with an
improved survival in 79% of cases, contrary to expected
results [68]. These results highlight the need for further
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Figure 1: Potential factors involved in the organ-speciﬁc metastasis
of breast cancer to the brain, liver, lymph nodes, lung, and
bone. Brain, lung, and liver images were acquired with thanks to
Creative Commons Licensing (CC0 1.0, Public Domain Dedica-
tion). Bone image from Gray’s Anatomy (1918, Public Domain,
copyright expired). Underlining indicates tumor-derived factors.
Italics indicate organ-derived factors. ∗indicates factor identiﬁed by
microarray analysis of organ-speciﬁc metastatic cell line variants
[56–59].
investigation of the interaction between breast cancer cells
and the bone microenvironment as it appears to be more
complex than originally thought.
7.2. Brain. The brain represents a unique metastatic niche.
It is judiciously guarded by the blood-brain barrier (BBB), a
continuous sheet of nonfenestrated endothelium joined by
tight junctions and supported by a basement membrane,
pericytes and astrocytes [69]. These endothelial cells are
armed with ATP-binding cassette C1 (ABCC1) and P-
glycoprotein (PGP/ABCB1) and are thus capable of active
eﬄux of most chemotherapeutic drugs from the brain
parenchyma [70]. The mechanism by which tumor cells6 International Journal of Breast Cancer
traverse the BBB is poorly understood, but it is postulated
that tumor cells adhere to the endothelium and promote
endothelial retraction to expose the basement membrane
and allow for tumor cell invasion [71].
Brain metastases are associated with later stages of
disease progression and often only occur secondary to other
metastatic lesions in the bone, lung, and/or liver [72]. Thus,
brain metastases may potentially represent the manifestation
of the true metastatic cascade, or metastasis of metastases
[10]. This theory suggests that primary tumor cells ﬁrst
colonize a visceral organ or regional lymph node before
acquiring the phenotype necessary to successfully traverse
the BBB and interact with the brain microenvironment.
Once inside the brain parenchyma, tumor cells encounter
a rich microenvironment of cytokines and growth factors,
predominantly produced by astrocytes (i.e., SDF-1α [73], IL-
1, IL-3, IL-6, interferon-γ (IFN-γ), tumor necrosis factor-α
(TNF-α), TGF-β, and PDGF-1 [74]), which the tumor cells
usurp to promote survival, growth, and potentially organ-
speciﬁc metastasis [62]. Furthermore, astrocytes have been
shown to exert a tumor-protective eﬀect from chemother-
apeutics via direct cell-cell contact [75]. It is likely that
a combination of these factors contributes to the highly
resistant nature of brain metastases to therapeutics and
must be taken into account for the development of new
therapeutics.
Further insight into the interactions between tumor
cells and the brain microenvironment has been elegantly
demonstrated by isolation of a brain-speciﬁc metastatic
variant of the MDA-MB-231 human breast cancer cell
line through repeated selection in vivo by Bos and col-
leagues [56]. Genetic comparison with the parental line
highlighted increased expression in the brain variant of
cyclooxygenase-2 (COX2), heparin-binding EGF (HBEGF),
and sialyltransferase ST6 (alpha-N-acetyl-neuraminyl-2,3-
beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sial-
yltransferase 5 (ST6GALNAC5) as potential facilitators of
tumor-cell passage through the BBB. Additionally, the
authors highlighted collagenase-1 (MMP1), angiopoietin-
like 4 (ANGPTL4), latent TGF-β-binding protein (LTBP1),
and fascin-1 (FSCN1) as genes that were upregulated in
the brain-seeking population and thus, potential mediators
of brain metastasis, providing more insight into possible
tumor-speciﬁc therapeutic targets.
7.3. Lung. The physical characteristics of the lung make
it an ideal site for colonization and eventual outgrowth
of tumor cells. The combination of immense surface area
and numerous capillaries make it likely that tumor cells
will lodge in the vasculature by sheer mechanical forces.
The CXCR4/SDF-1 and chemokine (C-C motif) receptor
7/chemokine (C-C motif) ligand 21 (CCR7/CCL21) inter-
actions may play key roles in accentuating the adhesion of
tumor cells as the lung endothelium expresses a high level of
SDF-1 and CCL21 to complement tumor cell expression of
CXCR4 and CCR7 [62, 76]. Additionally, the growth factor
transferrin has been suggested to have protumor eﬀects on
cells that have the potential to metastasize to the lung but not
to their nonmetastatic counterparts [77]. In a Neu-induced
transgenic mouse model of breast cancer, TGF-β functioned
to promote lung metastases [78], in agreement with the well-
established multifunctionality of TGF-β as being a tumor
suppressor in the early stages of cancer, but a metastatic
promoter in late stages [79].
Genetic analysis of a lung-speciﬁc metastatic variant
of the MDA-MB-231 human breast tumor cell line has
identiﬁed several genes that appear to mediate successful
lung metastasis. Minn et al. [58] highlight a combination
of secretory and receptor proteins including EGF family
member, epiregulin (EREG), CXCL1, MMP1 and 2, cell
adhesion molecules secreted protein acidic and rich in
cysteine (SPARC; osteonectin) and vascular cell adhesion
molecule1(VCAM1),andtheIL-13decoyreceptorIL13Rα2.
Further analysis of this lung-targeting variant has high-
lighted the increased expression of tenascin C (TNC) when
compared to the parental MDA-MB-231 line. TNC is a
component of the extracellular matrix, and the authors
suggest that tumor-secreted TNC plays an important role in
determining the metastasis initiating capacity of a cell [59].
While there is some overlap between gene expression proﬁles
of organ-speciﬁc variants of the same cell line, enough of a
discrepancy exists that there are clear lung, bone, and brain
metastasis signatures.
7.4. Liver. The prevalence of liver metastases in colon cancer
far exceeds that of breast cancer, which has resulted in more
research being done on the former. Consequently, identiﬁed
interactions between colon cancers and hepatic metastases
may not apply to breast cancers. However, hints about the
metastaticmechanismsofbreastcancerdoarise intheobser-
vation of liver colonization by breast cancer cells. In a study
by Stessels et al., 43 out of 45 breast cancer cases examined
withlivermetastasesexhibitedwhatisknownasreplacement
growth, where tumor cells displace hepatocytes to coopt the
sinusoidal blood vessels while preserving liver architecture
[80]. This method of colonization allows for tumor growth
independent of angiogenesis. To date, liver-targeting breast
cancer cell line variants have not been established, but once
selected for, genetic comparison between the organ-speciﬁc
variantsmentionedabovewillprovideinvaluableinsightinto
the mechanisms driving liver-speciﬁc metastatic disease.
7.5. Lymph Nodes. In addition to hematogenous dissemina-
tion, breast cancer cells may also metastasize via the lym-
phatic system. Metastatic tumor cells may either stimulate
lymphangiogenesis and enter the nascent vessels or may
invade into preexisting lymphatic vasculature. Important
primary tumor-derived signals may stem from the VEGF-
C/VEGF-D activation of lymphatic endothelial VEGFR-3,
which stimulates lymphangiogenesis toward the primary
tumorandallowsforcellulardissemination[81].Conversely,
molecules proposed to be direct mediators of lymphatic
colonizationincludeCCL21andSDF-1interactingwiththeir
tumor-expressed receptors, CCR7 and CXCR4, respectively.
Thesepairsplayimportantrolesinthephysiologichomingof
lymphoid or hematopoietic cells, and their ligands are highly
expressed in the lymph nodes. Additionally, blocking of the
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invivomodelofbreastcancermetastasissuccessfullyblocked
metastases to the axillary lymph nodes [62].
A lymph node speciﬁc variant (468LN) of the MDA-
MB-468 breast cancer cell line has been isolated and its
mRNA expression compared to a variant of low lymphatic
metastatic capacity (468GFP) [82]. When genes identiﬁed by
diﬀerential expression were further compared to gene sets
identiﬁed through clinical observations to ensure relevance,
pathways associated with cell survival and growth in for-
eign environments were highlighted. Of note, E-cadherin,
insulin-like growth factor binding protein 3 (IGFBP3),
MAP-kinase activating death domain (MADD), and tissue
inhibitor of metalloproteinase 3 (TIMP3) were downreg-
ulated, while cyclin-dependent kinase 2 (CDK2), SPARC,
OPN, and vimentin were all upregulated. Additionally, the
468LN line harbored a larger CD44+ CD24− population
(96.4%) than the 468GFP line (6.3%) suggesting a role for
breast CSCs in mediating this metastatic capacity.
Thefactorsthathavebeendiscussedaboveforthevarious
metastatic niches represent a brief summary of what is
known and are not exhaustive. The diversity of the potential
interactions between seed and soil highlights the need for
further research. In particular, the question of whether
the presence of the primary tumor can inﬂuence micro-
environmental changes in distant organs prior to tumor cell
arrival and metastatic colonization is intriguing.
8.Preppingthe “Soil”:The PremetastaticNiche
Recent work has shown that primary tumors may play an
important role in creating a “premetastatic niche” prior to
cancer cell arrival at secondary sites. Work by Kaplan et al.
[83] highlighted the role of vascular endothelial growth fac-
torreceptor-1positive(VEGFR1+)hematopoieticprogenitor
cells (HPCs) in the creation of this niche. When signals
from the primary tumor tip the normal balance between
pro- and antiangiogenic signals in favor of angiogenesis,
the angiogenic switch is triggered, causing the recruitment
of new vessels to the tumor site [84]. During this process,
HPCs are mobilized and migrate towards the tumor-speciﬁc
premetastatic niche where they form clusters. Characteri-
zation of these cells revealed conserved progenitor markers
of CD133, CD34, CD117 (c-Kit) in addition to expression
of very late antigen-4 (VLA-4; integrin α4β1), suggesting
a VLA-4-ﬁbronectin interaction between migrating HPCs
and the new microenvironment. Additionally, MMP9 was
expressed by the premetastatic clusters, potentially due to
integrin-dependent activation of VEGFR1+ HPCs, thereby
altering the microenvironment through the breakdown
of basement membranes and resultant release of soluble
Kit-ligand. This study further showed that the VEGFR1+
cells supported tumor cell adherence and growth and that
metastasis could be abrogated upon the treatment with an
anti-VEGFR1 antibody, highlighting the importance of these
clusters in the creation of the premetastatic niche [83].
Another method that tumors use to condition the
metastatic niche relies on microvesicular (MV) deposition
of factors. Tumor-derived MVs, or exosomes, are derived
from the inner membranes of the late endosomes and range
from 40 to 100nm in diameter. Release into the surrounding
tissue or bloodstream occurs when the endosomes fuse with
the cellular membrane [85]. Although the underlying mech-
anism is not fully understood, MVs may stimulate target
cellular receptors directly, transfer surface receptors from cell
to cell, deliver proteins [86], or may even cause epigenetic
reprogramming of cells [87]. Additionally, MVs have been
found to harbor immunosuppressive molecules [88]. Thus,
exosomes may provide important signals to the tumor cells
once they arrive in the metastatic niche, in addition to
sculpting the stromal and immune cells systemically.
A recent concern arising from the revelation that exo-
somes are functional moieties and not just carriers of
cellular waste arises from the potential for horizontal gene
transfer between tumor cells and bone-marrow-derived cells
(BMDCs) recruited to the premetastatic niche. Lyden and
colleagues call this phenomenon “tumor exosome-driven
education” of BMDCs [89]. This process likely promotes the
progrowth and survival environment of the niche and may
potentiate the metastatic process. Given their multifunction-
ality, it is likely that tumor-derived exosomes contribute to
the creation of the premetastatic niche. Therefore, although
the immunosuppressive eﬀects of exosomes must ﬁrst be
negated, exosomes may represent a novel cell-free source of
tumor antigens that can be utilized in the creation of an anti-
cancer immunization to enhance the anti-tumor immune
response [90].
9.The CancerStemCellNiche: DoesItExist?
To date, published literature has used whole cell populations
of organ-speciﬁc metastatic variants of human tumor cell
linesasamodeltoinvestigatetheorgantropismofmetastasis
[56–58]. However, these studies have overlooked the involve-
ment of CSCs in this process. Further characterization of
the distinct subpopulation of CSCs within these metastatic
variants is needed to see if more reﬁned genetic signatures
can be obtained, possibly dictating a more speciﬁc niche for
metastasis. If CSCs are indeed the initiators of metastasis, it
is important to determine if these cells also exhibit organ-
speciﬁc behaviors or if they are innately more metastatic
to all sites in a nonspeciﬁc manner. Further investigations
could also include murine models of spontaneous metastasis
utilizing CSC and non-CSC subpopulations to elucidate if
both subpopulations equally recruit the VEGFR1+ popula-
tionobservedbyKaplanetal.[83]tothepremetastaticniche,
or if this capacity resides within one subpopulation. Our
lab has observed increased tumorigenicity and metastatic
ability to the lung of stem-like ALDHhi CD44+ stem-like
breast cancer cells relative to nonstem-like ALDHlow CD44−
cells [18]. This observed metastatic proﬁciency of CSCs
may be partially attributed to their ability to create the
premetastatic niche, in addition to their ability to form
signiﬁcant primary tumors. However, the exact mechanism
behindthisincreasedmetastaticpotentialremainsunknown.
Additional characterization of the cell surface molecules
expressed by CSCs may also provide further insight into
their roles in metastatic organ tropism. For example, CSC
expression of receptors such as CXCR4 would confer speciﬁc8 International Journal of Breast Cancer
targeting to areas where SDF-1 is highly expressed, such
as bone, lung, lymph node, and brain [62, 73, 76], where
the cells would then receive additional signals to support
colonization. Additionally, CSCs may express higher levels
of cell-surface receptors than their non-CSC counterparts
so that they may fully harness the soluble growth factors
presentatsecondarysites,conferringagrowthadvantageand
permitting successful colonization.
10. Therapeutic Implications/Conclusions
A better understanding of the mechanism underlying the
metastatic process is needed in order to increase the
eﬃcacy of treatments against this lethal process of disease
progression. Metastatic lesions are often highly resistant to
therapies, possibly due to the resident CSCs. In breast cancer,
it would appear that the purported CSC subpopulation also
encompasses the metastasis-initiating population. A better
understanding of the interactions between CSCs and host
organs may therefore lead to the identiﬁcation of new targets
that may allow for the abrogation of metastatic growth
signals and consequently successful targeting of metastatic
disease. Conversely, innate inhibitory factors may be found
in the hostile secondary organs that may also be harnessed
for therapeutic purposes. The deﬁnition of the microenvi-
ronment has evolved to include soluble factors, extracellular
matrix, cell surface molecules, chemokines, hormones, and
now exosomes, widening the scope of interactions that must
be investigated.
There is no question that the clinically observed patterns
of metastasis are relevant for cancer therapy, as there must
be speciﬁc organ-cancer cell interactions contributing to the
viewed success and failures of cancer cells to colonize speciﬁc
secondary sites. In addition to targeting tumor-secreted
factors, research is needed to identify key innate factors
providing attractive and/or growth signals for the arriving
cancer cells, so that inhibitors or speciﬁc targeting molecules
may be developed against these factors. Furthermore, eluci-
dation of the role of CSCs in this metastatic organ-tropism
is also important, as new therapies are required to target this
innately therapeutic resistant subpopulation. In light of the
potential for interconversion between non-CSCs and CSCs,
new therapies must target both populations of cells to be
eﬀective.
Further understanding of the role of CSCs in metastasis
can be acquired with the characterization of circulating
tumor cells (CTCs). Research in the CTC ﬁeld is rapidly
developing, and innovative techniques for the capture and
characterization of CTCs are rapidly evolving. The many
platforms to date (eloquently reviewed by Lowes et al.
[91]a n dY ue ta l .[ 92]) allow researchers to choose their
method of capture based on either molecular cellular
characteristics such as epithelial cell adhesion molecule
(EpCAM)+CD45−Cytokeratin 8, 18, and 19+ (CellSearch;
Veridex), EpCAM+ (microﬂuidic CTC-chip [93, 94]), or
markers of the researcher’s choice (Fiber-optic array scan-
ning technology [95, 96]), or physical cell size (ﬁlter-
based platforms [97, 98]). Regardless of the platform, these
techniques will allow for the further characterization of
CTCs providing insight into the mechanisms driving organ
tropism and whether CSCs are involved. Additionally, CTC
data will oﬀer distinct beneﬁts for individualized therapy, as
physicians could tailor therapy to the characteristics of the
CTCs.
As the world’s population ages, the incidence of cancer is
projected to increase, making more eﬀective treatments vital
to help combat this growing world-wide burden. Although
methods for early detection are in place for more developed
countries, these capacities are not readily available in devel-
oping countries. Thus, cancers in these areas will often be
detected during the later stages of disease progression, when
metastasis has likely already occurred. Novel, more eﬀective
metastatic treatments may be the only option for this new
group of cancer patients and are already desperately required
for those in developed countries burdened with metastatic
breast cancer. In addition to further understanding the
characteristics of cancer stem cells, future research should
focus on the interactions between CSCs and the secondary
organs of metastasis, as we believe this to be where new
metastatic targets will arise.
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